R

    RenovoRx Inc (RNXT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.93
    +0.26 (+15.57%)

    Market Cap: $75.37M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    76%(16/21)
    Avg Surprise
    +3.78%
    Streak
    10 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.03
    Range$-0.03 - $-0.03
    1 analysts
    EPS RevisionsNo revisions (7d)
    1
    1
    30d
    EPS Estimate Drift
    90d ago$-0.08-166.7%
    60d ago$-0.07-150.0%
    30d ago$-0.07-150.0%
    7d ago$-0.07-150.0%
    Current$-0.03
    Revenue Consensus
    $952000
    Range$550000 - $1M
    4 analysts
    Dec 31, 2026
    EPS Consensus$-0.11
    Range$-0.11 - $-0.11
    1 analysts
    Revenue Consensus
    $2M
    Range$644000 - $2M
    4 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.11---
    Sep 26EST
    		-$-0.03---
    Jun 26
    		$-0.05$-0.08+37.50%Beat+37.5%
    Mar 26
    		$-0.08$-0.08+0.00%Beat+0.0%
    Dec 25
    		$-0.08$-0.08+0.00%Beat+33.3%
    Sep 25
    		$-0.08$-0.08+0.00%Beat+20.0%
    Jun 25
    		$-0.08$-0.08+0.00%Beat+20.0%
    Mar 25
    		$-0.08$-0.08+0.00%Beat+73.3%
    Dec 24
    		$-0.12$-0.13+4.00%Beat+61.3%
    Sep 24
    		$-0.10$-0.12+16.67%Beat+23.1%
    Jun 24
    		$-0.10$-0.11+9.09%Beat+54.5%
    Mar 24
    		$-0.30$-0.30+0.00%Beat+16.7%
    Dec 23
    		$-0.31$-0.30-3.33%Miss-34.8%
    Sep 23
    		$-0.13N/A+53.57%Beat+45.8%
    Jun 23
    		$-0.22$-0.29+24.14%Beat+24.1%
    Mar 23
    		$-0.36$-0.25-44.00%Miss-9.1%
    Dec 22
    		$-0.23$-0.26+11.54%Beat-91.7%
    Sep 22
    		$-0.24$-0.29+17.24%Beat+11.1%
    Jun 22
    		$-0.29$-0.28-3.57%Miss+39.6%
    Mar 22
    		$-0.33$-0.21-57.14%Miss+42.4%
    Dec 21
    		$-0.12$-0.16+25.00%Beat+76.6%
    Sep 21
    		$-0.27$-0.21-28.57%Miss+22.5%
    Jun 21
    		$-0.48$-0.58+17.24%Beat-0.3%
    Mar 21
    		$-0.57$0.00N/AMiss-
    Dec 20
    		$-0.51$0.00N/AMiss-
    Mar 20
    		$-0.35$0.00N/AMiss-
    Dec 19
    		$-0.48$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-6.66EV/EBITDA-4.72x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin-368.40%
    ROE-125.20%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio5.74xQuick Ratio5.53x
    Trading Statistics
    Beta0.99Avg Volume744.17K
    52-Week High$1.6852-Week Low$0.70

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.44
    SMA 20$1.30
    SMA 50$1.07
    SMA 200$0.96
    EMA 10$1.50
    EMA 20$1.34
    EMA 50$1.15
    EMA 200$1.02

    MACD

    Line: 0.17Signal: 0.12Hist: 0.05

    ADX

    ADX: 55.3+DI: 42.7-DI: 4.7

    Aroon & PSAR

    Aroon Up100.0
    Aroon DownN/A
    PSAR$1.17

    Bollinger Bands

    Upper Band$1.74
    Lower Band$0.86
    %B Position6740%(Upper)
    Band Width1.22

    RSI (14-Day)

    Overbought
    80.2

    Momentum Oscillators

    Stoch %K92.3
    Stoch %D87.0
    Williams %R-4.6
    ROC (10d)60.8%
    Momentum0.73
    CCI (20d)253.5
    MFI (14d)82.0

    Volatility Measures

    ATR (14d)$0.15(7.5%)
    StdDev (20d)0.22
    Hist Vol124.8%(High)

    Volume Flow

    VWAP$1.85
    OBV7.1M
    AD Line-10.5M
    CMF (20d)0.288

    Volume Metrics

    Avg Vol (20d)746.2K
    Vol Ratio4.4x(High)
    VWMA (20d)$1.45

    Pivot Points

    R3$1.95
    R2$1.81
    R1$1.74
    Pivot Point$1.61
    S1$1.53
    S2$1.40
    S3$1.33

    Advanced Oscillators

    TSI40.05
    Ultimate Osc64.0
    KST471.59

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$909,000$563,000$238,000$266,000$422,000$197,000$43,000$0$0$0$0$0
    Cost of Revenue$143,000$84,000$28,000$53,000$152,000$94,000N/A$0$0$0N/A$0
    Gross Profit$766,000$479,000$210,000$213,000$270,000$103,000$43,000$0$0$0N/A$0
    Operating Expenses$4.12M$3.95M$3.73M$3.41M$2.95M$3.21M$2.67M$2.83M$3.03M$2.48M$1.78M$2.98M
    R&D$1.20M$1.23M$1.52M$1.69M$1.43M$1.64M$1.58M$1.65M$1.54M$1.26M$775,000$1.63M
    SG&A$2.92M$2.72M$2.22M$1.73M$1.52M$1.57M$1.10M$1.18M$1.49M$1.22M$1.00M$1.35M
    Operating Income$-3,349,000$-3,469,000$-3,522,000$-3,200,000$-2,678,000$-3,110,000$-2,632,000$-2,828,000$-3,034,000$-2,476,000$-1,777,000$-2,983,000
    Interest Income$90,000$45,000$75,000$113,000$133,000$106,000$85,000$124,000$138,000$37,000$11,000$43,000
    Interest Expense$0$52,000$0$0$217,000$0$246,000$0$0$0$1.45M$0
    Income Before Tax$-2,911,000$-3,521,000$-2,941,000$-2,912,000$-2,895,000$-2,420,000$-2,878,000$-2,471,000$-2,389,000$-1,076,000$-3,227,000$-1,421,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-2,911,000$-3,521,000$-2,941,000$-2,912,000$-2,895,000$-2,420,000$-2,878,000$-2,471,000$-2,389,000$-1,076,000$-3,227,000$-1,421,000
    EBITDA$-2,994,000$-3,565,000$-3,015,000$-3,026,000$-3,027,000$-2,525,000$-2,963,000$-2,595,000$-2,527,000$-1,113,000$-1,777,000$-1,464,000
    EBIT$-2,999,000$-3,566,000$-3,016,000$-3,025,000$-3,028,000$-2,526,000$-2,963,000$-2,595,000$-2,527,000$-1,113,000$-1,777,000$-1,464,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about RNXT

    News

    RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic Data Supporting TAMP Platform's Targeted Drug-Delivery in Locally Advanced Pancreatic Cancer

    RenovoRx announced the peer-reviewed publication of pharmacokinetic and pharmacodynamic (PK/PD) data from a sub-study of its Phase III TIGeR-PaC clinical trial in locally advanced pancreatic cancer (LAPC). The study, published in Cancer Chemotherapy and Pharmacology, demonstrates that the company's TAMP platform, utilizing the RenovoCath device, concentrates chemotherapy at the tumor site with significantly reduced systemic exposure. These findings provide strong mechanistic support for the targeted drug-delivery approach and its potential to improve treatment efficacy while limiting side effects in LAPC patients.

    Investing News Network•8/25/26•
    Bullish

    RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic (PK/PD) Data Supporting TAMP™ Platform’s Targeted Drug-Delivery in Locally Advanced Pancreatic Cancer

    RenovoRx (Nasdaq: RNXT) has published peer-reviewed data from a sub-study of its Phase III TIGeR-PaC trial, demonstrating that its TAMP-mediated intra-arterial gemcitabine delivery achieved approximately 51% local drug extraction at the tumor site in pancreatic cancer patients. The study also showed significantly reduced systemic exposure to gemcitabine and a correlation between drug metabolite levels and tumor marker reduction. These findings support the TAMP platform's potential for targeted drug delivery while minimizing systemic side effects.

    Stock Titan•8/25/26•
    Bullish

    RenovoRx receives U.S. patent allowance for cancer device

    RenovoRx, Inc. announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for its patent application covering the RenovoCath, a dual-occlusion catheter for targeted cancer therapy delivery. This adds to their global intellectual property portfolio of 20 issued or allowed patents. The company is currently conducting a Phase III clinical trial for RenovoCath with gemcitabine for pancreatic and bile duct cancer, which has received Orphan Drug Designation.

    Investing.com•8/21/26•
    Bullish

    RenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement

    RenovoRx, Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement, following notification that its common stock closed at $1.00 or greater for 10 consecutive business days. The company's CEO, Shaun Bagai, highlighted recent achievements including record second-quarter revenue, growth in commercial cancer center customers for RenovoCath, and completion of enrollment in the Phase III TIGeR-PaC trial. RenovoRx aims to continue expanding its commercial footprint and advancing its clinical programs.

    Yahoo Finance•8/21/26•
    Bullish

    RenovoRx Receives Notice of Allowance for New U.S. Patent Covering RenovoCath®, an Advanced Dual-Occlusion Catheter, for Targeted Therapeutic Drug-Delivery for Cancer Treatment

    RenovoRx, Inc. announced that the USPTO has issued a Notice of Allowance for a new U.S. patent covering its RenovoCath® advanced dual-occlusion catheter. This patent strengthens the company's intellectual property portfolio, reinforcing its targeted drug-delivery approach for cancer treatment using the TAMP™ platform. The RenovoCath device is designed to deliver therapies directly to tumor sites, aiming to improve precision, effectiveness, and reduce systemic side effects.

    Investing News Network•8/20/26•
    Bullish

    Frequently Asked Questions About RNXT

    Does RNXT pay dividends?
    RenovoRx Inc (RNXT) does not currently pay a regular dividend.
    What is RNXT's market cap?
    RenovoRx Inc (RNXT) has a market capitalization of $75.37M with a current stock price of $1.93.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In